9 Amendments of Stanislav POLČÁK related to 2021/2013(INI)
Amendment 81 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
C a. whereas the overall consumption of pharmaceuticals continues to grow both globally and in the EU; whereas an important part of pharmaceuticals is prescribed, dispensed, sold or used inappropriately; whereas such misuse of pharmaceuticals means a waste of precious resources and can lead to health and environmental hazards;
Amendment 87 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
C a. whereas the shortage of medicines in the European Union has worsened, in particular as a result of increased global demand; whereas the European Union has lost pharmaceutical independence and self-sufficiency as a result of the relocation of production to third countries;
Amendment 106 #
Motion for a resolution
Recital C b (new)
Recital C b (new)
C b. whereas the transfer of production to third countries tends to be motivated by an attempt to reduce production costs; whereas these savings are mainly due to more lax environmental, safety and labour law standards;
Amendment 111 #
Motion for a resolution
Recital C c (new)
Recital C c (new)
C c. whereas there is convincing evidence that pharmaceuticals leach into the environment, in particular into soil and water; whereas their presence can have adverse effects on wild animals such as fish, birds and insects and, as a result, broader impacts on the stability of individual ecosystems; whereas these medicines also appear in drinking water at lower concentrations;
Amendment 423 #
Motion for a resolution
Paragraph 12
Paragraph 12
12. Insists that a competitive, self- sufficient and sustainable EU pharmaceutical industry is strategic and more responsive to patients’ needs; points out that the industry needs a stable, flexible and agile regulatory environment; believes that it can thrive globally with a clear, robust and efficient intellectual property system; welcomes the initiative to build the European Health Data Space and interoperable digital infrastructure for the European Health Data Space;
Amendment 590 #
Motion for a resolution
Paragraph 19
Paragraph 19
19. Recalls that the EU’s open strategic autonomy is linked to the constant and sufficient availability of medicines in all Member States; calls on the Commission to take steps in this direction leading to the strengthening of cooperation between Member States, in order to develop an early warning system for drug shortages, based on a European information network on supply problems, to increase public- private collaboration and to monitor the obligation on the part of industry to provide early and transparent information on the availability of medicines; calls on the Commission to develop a mechanism to safeguard transparency in production and supply chains in the event of emergencies;
Amendment 670 #
Motion for a resolution
Paragraph 22 a (new)
Paragraph 22 a (new)
22 a. Welcomes the Commission’s efforts to address the problem of pharmaceuticals in the environment; draws attention, in this connection, to the need to continue and to step up these efforts, in particular as regards investments in technologies providing more effective solutions for the removal of pharmaceuticals from waste water, the assessment of the environmental impact of veterinary medicines, the development of continuous monitoring and data sharing on potential significant sources of this type of pollution, and the improvement of the management of animal by-products containing pharmaceutical residues, such as antibiotics;
Amendment 673 #
Motion for a resolution
Paragraph 22 a (new)
Paragraph 22 a (new)
22 a. Is of the opinion that environmental sustainability of medicinal products cannot be achieved without proper assessment of environmental effects associated with their production and use; asks the Commission to ensure that negative environmental effects of medicinal products, both existing and new, are duly assessed and taken into account during the authorisation procedure or post-authorisation monitoring;
Amendment 680 #
Motion for a resolution
Paragraph 22 b (new)
Paragraph 22 b (new)
22 b. stresses that rational use of medicines and prevention of wastage are crucial in minimization of their negative environmental effects and can help to ensure that medicines are affordable and available for people who need them, especially from disadvantaged and vulnerable groups; asks the Commission to pay attention to the promotion of rational use of medicines, including by responsible prescribing, consumer awareness and technical measures such as reduction of pack sizes and their alignment to real use;